Spectral Diagnostics Inc. (OTCMKTS:EDTXF) Short Interest Update

Spectral Diagnostics Inc. (OTCMKTS:EDTXF) was the target of a large drop in short interest in the month of July. As of July 15th, there was short interest totaling 6,242 shares, a drop of 37.9% from the June 30th total of 10,049 shares. Based on an average daily trading volume, of 12,727 shares, the short-interest ratio is presently 0.5 days. Currently, 0.0% of the company’s shares are sold short.

Spectral Diagnostics Stock Down 0.6%

OTCMKTS EDTXF traded down $0.01 on Friday, hitting $0.99. The company’s stock had a trading volume of 2,000 shares, compared to its average volume of 9,133. Spectral Diagnostics has a 1-year low of $0.58 and a 1-year high of $1.31. The company’s 50-day moving average is $0.98 and its 200 day moving average is $0.99. The firm has a market cap of $290.32 million, a PE ratio of -9.89 and a beta of 0.11.

Spectral Diagnostics (OTCMKTS:EDTXF) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01). The business had revenue of $0.64 million for the quarter, compared to analyst estimates of $0.54 million.

Spectral Diagnostics Company Profile

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.